Oragenics Stock Today
| OGEN Stock | USD 0.28 0.01 3.45% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Oragenics is selling at 0.28 as of the 16th of March 2025; that is 3.45 percent decrease since the beginning of the trading day. The stock's open price was 0.29. Oragenics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of February 2004 | Category Healthcare | Classification Health Care |
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida. Oragenics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. The company has 13.71 M outstanding shares of which 392.6 K shares are now shorted by private and institutional investors with about 0.03 trading days to cover. More on Oragenics
Moving together with Oragenics Stock
| 0.7 | ENVB | Enveric Biosciences Earnings Call Next Week | PairCorr |
Moving against Oragenics Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Oragenics Stock Highlights
| CEO Director | Kimberly Murphy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOragenics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Oragenics' financial leverage. It provides some insight into what part of Oragenics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Oragenics (OGEN) is traded on NYSE MKT Exchange in USA. It is located in 4902 Eisenhower Boulevard, Tampa, FL, United States, 33634 and employs 5 people. Oragenics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.84 M. Oragenics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 13.71 M outstanding shares of which 392.6 K shares are now shorted by private and institutional investors with about 0.03 trading days to cover.
Oragenics currently holds about 17.87 M in cash with (7.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15.
Check Oragenics Probability Of Bankruptcy
Ownership AllocationOragenics has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Oragenics Ownership Details
Oragenics Historical Income Statement
Oragenics Stock Against Markets
Oragenics Corporate Management
| Martin MSc | VP Research | Profile | |
| MD MA | Chief Advisor | Profile | |
| IV FACEP | Chief Officer | Profile | |
| Erik Emerson | Chief Officer | Profile | |
| Michael CPA | S CFO | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oragenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oragenics. If investors know Oragenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oragenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Oragenics is measured differently than its book value, which is the value of Oragenics that is recorded on the company's balance sheet. Investors also form their own opinion of Oragenics' value that differs from its market value or its book value, called intrinsic value, which is Oragenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oragenics' market value can be influenced by many factors that don't directly affect Oragenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oragenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oragenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oragenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.